Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Pancreatic Neoplasms | 74 | 2024 | 5369 | 7.450 |
Why?
|
Carcinoma, Pancreatic Ductal | 39 | 2024 | 1728 | 6.220 |
Why?
|
Pancreatectomy | 21 | 2023 | 811 | 3.960 |
Why?
|
Hepatectomy | 13 | 2024 | 557 | 3.700 |
Why?
|
Pancreaticoduodenectomy | 18 | 2024 | 509 | 3.310 |
Why?
|
Liver Neoplasms | 20 | 2023 | 4319 | 2.640 |
Why?
|
Neoadjuvant Therapy | 32 | 2024 | 2827 | 2.150 |
Why?
|
Adenocarcinoma | 18 | 2023 | 6346 | 2.110 |
Why?
|
Carcinoma, Hepatocellular | 13 | 2023 | 2297 | 2.000 |
Why?
|
Hepatic Artery | 3 | 2024 | 232 | 1.460 |
Why?
|
Bile Duct Neoplasms | 6 | 2021 | 605 | 1.350 |
Why?
|
Cholangiocarcinoma | 5 | 2021 | 552 | 1.240 |
Why?
|
Venous Thromboembolism | 6 | 2022 | 1866 | 1.210 |
Why?
|
Cancer Care Facilities | 2 | 2020 | 422 | 1.090 |
Why?
|
Pancreatic Fistula | 4 | 2019 | 148 | 1.040 |
Why?
|
Leucovorin | 14 | 2024 | 643 | 1.000 |
Why?
|
General Surgery | 6 | 2023 | 1692 | 0.980 |
Why?
|
Surgical Wound Infection | 7 | 2018 | 1529 | 0.980 |
Why?
|
Colorectal Neoplasms | 11 | 2023 | 6935 | 0.960 |
Why?
|
Adenocarcinoma, Mucinous | 4 | 2023 | 517 | 0.960 |
Why?
|
Portal Vein | 4 | 2021 | 431 | 0.910 |
Why?
|
Fluorouracil | 17 | 2024 | 1642 | 0.910 |
Why?
|
Neoplasm Staging | 20 | 2023 | 11121 | 0.900 |
Why?
|
Healthcare Disparities | 4 | 2023 | 3358 | 0.860 |
Why?
|
Embolization, Therapeutic | 3 | 2021 | 1418 | 0.830 |
Why?
|
Pancreatic Cyst | 2 | 2024 | 367 | 0.830 |
Why?
|
Duodenal Neoplasms | 3 | 2023 | 114 | 0.810 |
Why?
|
Retrospective Studies | 68 | 2023 | 80646 | 0.800 |
Why?
|
Rectal Neoplasms | 2 | 2022 | 1157 | 0.800 |
Why?
|
Infusion Pumps | 1 | 2022 | 163 | 0.760 |
Why?
|
Patient Care Team | 3 | 2024 | 2521 | 0.740 |
Why?
|
Humans | 179 | 2024 | 761572 | 0.720 |
Why?
|
Neoplasms, Cystic, Mucinous, and Serous | 1 | 2023 | 194 | 0.720 |
Why?
|
Anastomosis, Surgical | 1 | 2024 | 983 | 0.720 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 20 | 2024 | 11742 | 0.680 |
Why?
|
Colorectal Surgery | 2 | 2019 | 122 | 0.670 |
Why?
|
Postoperative Complications | 15 | 2022 | 15633 | 0.670 |
Why?
|
Hospitals, General | 2 | 2022 | 798 | 0.670 |
Why?
|
Specialty Boards | 1 | 2020 | 235 | 0.610 |
Why?
|
Hypophosphatemia | 1 | 2018 | 92 | 0.600 |
Why?
|
Intraoperative Care | 3 | 2019 | 767 | 0.590 |
Why?
|
Symbiosis | 1 | 2020 | 294 | 0.580 |
Why?
|
Resuscitation Orders | 1 | 2019 | 270 | 0.580 |
Why?
|
Liver Failure | 2 | 2019 | 250 | 0.570 |
Why?
|
Survival Rate | 22 | 2024 | 12725 | 0.570 |
Why?
|
Chemoprevention | 1 | 2019 | 326 | 0.570 |
Why?
|
Neuroendocrine Tumors | 3 | 2024 | 641 | 0.560 |
Why?
|
Treatment Refusal | 1 | 2020 | 429 | 0.560 |
Why?
|
Pancreas | 6 | 2023 | 1691 | 0.550 |
Why?
|
Accreditation | 1 | 2020 | 473 | 0.550 |
Why?
|
Rectum | 2 | 2019 | 892 | 0.550 |
Why?
|
Anticoagulants | 5 | 2022 | 4812 | 0.530 |
Why?
|
Infusion Pumps, Implantable | 1 | 2017 | 158 | 0.530 |
Why?
|
Education, Medical, Graduate | 3 | 2020 | 2373 | 0.530 |
Why?
|
Malpractice | 1 | 2021 | 556 | 0.520 |
Why?
|
Coronavirus Infections | 4 | 2020 | 3086 | 0.510 |
Why?
|
Feasibility Studies | 2 | 2023 | 5247 | 0.510 |
Why?
|
Pneumonia, Viral | 4 | 2020 | 3206 | 0.510 |
Why?
|
Medicine | 1 | 2023 | 942 | 0.500 |
Why?
|
Gastrointestinal Neoplasms | 2 | 2020 | 954 | 0.500 |
Why?
|
Male | 93 | 2024 | 360842 | 0.490 |
Why?
|
Phosphates | 1 | 2018 | 770 | 0.490 |
Why?
|
Fluid Therapy | 1 | 2019 | 579 | 0.490 |
Why?
|
Hypothermia | 4 | 2012 | 188 | 0.480 |
Why?
|
Aged | 65 | 2024 | 169310 | 0.470 |
Why?
|
Laparoscopy | 5 | 2019 | 2036 | 0.470 |
Why?
|
Gallbladder Neoplasms | 1 | 2016 | 189 | 0.470 |
Why?
|
Burnout, Professional | 1 | 2023 | 704 | 0.460 |
Why?
|
Developed Countries | 1 | 2017 | 449 | 0.460 |
Why?
|
Conflict of Interest | 1 | 2019 | 554 | 0.450 |
Why?
|
Middle Aged | 73 | 2024 | 220920 | 0.450 |
Why?
|
SEER Program | 3 | 2020 | 1450 | 0.450 |
Why?
|
Home Care Services | 1 | 2020 | 648 | 0.440 |
Why?
|
Foreign Medical Graduates | 2 | 2011 | 77 | 0.440 |
Why?
|
Adenomatous Polyposis Coli | 1 | 2015 | 218 | 0.440 |
Why?
|
Exercise Therapy | 1 | 2020 | 929 | 0.430 |
Why?
|
Disclosure | 1 | 2019 | 748 | 0.430 |
Why?
|
Educational Measurement | 1 | 2020 | 1255 | 0.420 |
Why?
|
Pulmonary Embolism | 3 | 2019 | 2567 | 0.420 |
Why?
|
Oxygen | 4 | 2012 | 4227 | 0.410 |
Why?
|
Female | 83 | 2024 | 392686 | 0.410 |
Why?
|
Postcholecystectomy Syndrome | 1 | 2011 | 3 | 0.400 |
Why?
|
Necrolytic Migratory Erythema | 1 | 2011 | 1 | 0.400 |
Why?
|
Glucagonoma | 1 | 2011 | 14 | 0.400 |
Why?
|
Preoperative Care | 2 | 2020 | 2242 | 0.400 |
Why?
|
Choledochostomy | 1 | 2011 | 16 | 0.400 |
Why?
|
Prognosis | 25 | 2023 | 29629 | 0.400 |
Why?
|
Patient Readmission | 5 | 2023 | 3271 | 0.390 |
Why?
|
Publishing | 1 | 2019 | 833 | 0.390 |
Why?
|
Learning | 2 | 2021 | 1740 | 0.380 |
Why?
|
Clinical Protocols | 4 | 2020 | 1440 | 0.380 |
Why?
|
Referral and Consultation | 2 | 2024 | 3600 | 0.370 |
Why?
|
Bacterial Infections | 2 | 2010 | 1391 | 0.370 |
Why?
|
Sepsis | 6 | 2019 | 2585 | 0.370 |
Why?
|
Peritonitis | 2 | 2011 | 368 | 0.370 |
Why?
|
Carbohydrates | 2 | 2023 | 390 | 0.370 |
Why?
|
Mesenteric Veins | 2 | 2021 | 86 | 0.370 |
Why?
|
United States | 24 | 2023 | 72335 | 0.370 |
Why?
|
Immunity, Innate | 4 | 2010 | 3066 | 0.360 |
Why?
|
Lymph Nodes | 6 | 2024 | 3466 | 0.360 |
Why?
|
Chemotherapy, Adjuvant | 8 | 2023 | 3514 | 0.350 |
Why?
|
Yttrium Radioisotopes | 2 | 2021 | 107 | 0.350 |
Why?
|
Peritoneal Lavage | 1 | 2010 | 30 | 0.350 |
Why?
|
Pancreatic Ducts | 2 | 2024 | 329 | 0.350 |
Why?
|
Surgical Procedures, Operative | 6 | 2019 | 1924 | 0.340 |
Why?
|
Internship and Residency | 3 | 2023 | 5882 | 0.340 |
Why?
|
Infusions, Intra-Arterial | 2 | 2022 | 221 | 0.340 |
Why?
|
Thrombosis | 2 | 2020 | 2942 | 0.320 |
Why?
|
Databases, Factual | 9 | 2021 | 7967 | 0.310 |
Why?
|
Treatment Outcome | 23 | 2024 | 64684 | 0.310 |
Why?
|
Medical Oncology | 1 | 2020 | 2321 | 0.310 |
Why?
|
Hyperoxia | 1 | 2010 | 258 | 0.310 |
Why?
|
Colonic Neoplasms | 1 | 2020 | 2538 | 0.300 |
Why?
|
Judgment | 1 | 2010 | 273 | 0.300 |
Why?
|
Videoconferencing | 2 | 2020 | 203 | 0.300 |
Why?
|
Chemotaxis, Leukocyte | 1 | 2010 | 662 | 0.290 |
Why?
|
Caregivers | 4 | 2023 | 2238 | 0.280 |
Why?
|
Hospital Mortality | 6 | 2021 | 5293 | 0.280 |
Why?
|
Physicians | 2 | 2019 | 4591 | 0.280 |
Why?
|
Antineoplastic Agents | 6 | 2020 | 13642 | 0.280 |
Why?
|
Kaplan-Meier Estimate | 8 | 2021 | 6484 | 0.280 |
Why?
|
Hospitals, Urban | 1 | 2009 | 500 | 0.280 |
Why?
|
Positron-Emission Tomography | 6 | 2024 | 6485 | 0.280 |
Why?
|
Blood | 1 | 2009 | 596 | 0.270 |
Why?
|
Pandemics | 4 | 2020 | 8656 | 0.270 |
Why?
|
Common Bile Duct Neoplasms | 2 | 2023 | 120 | 0.270 |
Why?
|
CA-19-9 Antigen | 3 | 2022 | 106 | 0.270 |
Why?
|
Ampulla of Vater | 2 | 2023 | 149 | 0.260 |
Why?
|
Mycoses | 1 | 2009 | 386 | 0.260 |
Why?
|
Oxygen Inhalation Therapy | 1 | 2009 | 411 | 0.250 |
Why?
|
Mental Health | 1 | 2020 | 3250 | 0.250 |
Why?
|
Cause of Death | 3 | 2020 | 3683 | 0.250 |
Why?
|
Neoplasm Recurrence, Local | 8 | 2023 | 9280 | 0.250 |
Why?
|
Catheter Ablation | 1 | 2019 | 2751 | 0.250 |
Why?
|
Klebsiella pneumoniae | 2 | 2021 | 250 | 0.240 |
Why?
|
Aged, 80 and over | 19 | 2024 | 58986 | 0.240 |
Why?
|
Survival Analysis | 12 | 2021 | 10090 | 0.240 |
Why?
|
Hospice Care | 2 | 2023 | 678 | 0.240 |
Why?
|
HLA-DR Antigens | 3 | 2010 | 602 | 0.240 |
Why?
|
Massachusetts | 4 | 2021 | 8830 | 0.230 |
Why?
|
Length of Stay | 6 | 2022 | 6426 | 0.230 |
Why?
|
Hepatic Stellate Cells | 1 | 2024 | 119 | 0.220 |
Why?
|
Adult | 35 | 2024 | 221203 | 0.220 |
Why?
|
Analgesia, Patient-Controlled | 1 | 2024 | 116 | 0.220 |
Why?
|
Combined Modality Therapy | 5 | 2022 | 8528 | 0.220 |
Why?
|
Lymphatic Metastasis | 5 | 2024 | 2915 | 0.220 |
Why?
|
Liver Cirrhosis | 3 | 2024 | 1935 | 0.210 |
Why?
|
Workload | 1 | 2009 | 844 | 0.210 |
Why?
|
Telemedicine | 1 | 2020 | 3052 | 0.210 |
Why?
|
Multivariate Analysis | 6 | 2021 | 12059 | 0.200 |
Why?
|
Adenocarcinoma, Papillary | 1 | 2021 | 84 | 0.190 |
Why?
|
Tumor Microenvironment | 3 | 2024 | 3877 | 0.190 |
Why?
|
Personnel Selection | 2 | 2020 | 196 | 0.190 |
Why?
|
Dilatation | 1 | 2023 | 306 | 0.190 |
Why?
|
Dilatation, Pathologic | 1 | 2023 | 527 | 0.190 |
Why?
|
Pneumoperitoneum | 1 | 2021 | 46 | 0.190 |
Why?
|
Neuroectodermal Tumors, Primitive | 1 | 2022 | 136 | 0.190 |
Why?
|
Collagen Type I | 1 | 2024 | 616 | 0.180 |
Why?
|
Cystadenoma, Serous | 1 | 2021 | 100 | 0.180 |
Why?
|
Host-Pathogen Interactions | 1 | 2009 | 1459 | 0.180 |
Why?
|
Propensity Score | 3 | 2023 | 1913 | 0.180 |
Why?
|
Quality Assurance, Health Care | 1 | 2011 | 2169 | 0.180 |
Why?
|
Nomograms | 1 | 2022 | 230 | 0.180 |
Why?
|
Hospices | 1 | 2023 | 245 | 0.180 |
Why?
|
Liability, Legal | 1 | 2022 | 210 | 0.180 |
Why?
|
Perioperative Care | 4 | 2012 | 1036 | 0.180 |
Why?
|
Bile | 1 | 2021 | 298 | 0.180 |
Why?
|
Depression | 1 | 2020 | 8124 | 0.180 |
Why?
|
Kentucky | 2 | 2011 | 84 | 0.170 |
Why?
|
Klebsiella Infections | 1 | 2021 | 146 | 0.170 |
Why?
|
Appendicitis | 2 | 2022 | 675 | 0.170 |
Why?
|
Convalescence | 1 | 2020 | 105 | 0.170 |
Why?
|
Hyperplasia | 1 | 2023 | 1152 | 0.170 |
Why?
|
Blood Glucose | 3 | 2010 | 6391 | 0.170 |
Why?
|
Cholangitis | 1 | 2020 | 111 | 0.170 |
Why?
|
Diverticulitis | 1 | 2022 | 185 | 0.160 |
Why?
|
Delivery of Health Care | 1 | 2017 | 5336 | 0.160 |
Why?
|
Venous Thrombosis | 1 | 2008 | 1303 | 0.160 |
Why?
|
Medical Assistance | 1 | 2019 | 108 | 0.160 |
Why?
|
Bacteria | 1 | 2009 | 2199 | 0.160 |
Why?
|
Biliary Tract Neoplasms | 1 | 2020 | 185 | 0.150 |
Why?
|
Vascular Surgical Procedures | 2 | 2021 | 1489 | 0.150 |
Why?
|
Time Factors | 8 | 2021 | 39970 | 0.150 |
Why?
|
Rectal Diseases | 1 | 2019 | 143 | 0.150 |
Why?
|
Comprehension | 1 | 2023 | 621 | 0.150 |
Why?
|
Reactive Oxygen Species | 3 | 2010 | 2141 | 0.150 |
Why?
|
Colonic Diseases | 1 | 2019 | 201 | 0.150 |
Why?
|
Adolescent | 13 | 2023 | 88324 | 0.150 |
Why?
|
Quinolones | 1 | 2021 | 378 | 0.150 |
Why?
|
Anti-Bacterial Agents | 2 | 2021 | 7407 | 0.150 |
Why?
|
Losartan | 1 | 2019 | 265 | 0.140 |
Why?
|
Follow-Up Studies | 11 | 2021 | 39107 | 0.140 |
Why?
|
Tomography, X-Ray Computed | 10 | 2022 | 20571 | 0.140 |
Why?
|
Weight Loss | 3 | 2022 | 2684 | 0.140 |
Why?
|
Magnetic Resonance Imaging | 8 | 2024 | 36429 | 0.140 |
Why?
|
Physical Exertion | 1 | 2020 | 667 | 0.140 |
Why?
|
Cost-Benefit Analysis | 2 | 2020 | 5492 | 0.140 |
Why?
|
Quality Indicators, Health Care | 3 | 2012 | 1792 | 0.140 |
Why?
|
Body Temperature | 2 | 2010 | 781 | 0.140 |
Why?
|
Single-Cell Analysis | 2 | 2024 | 2450 | 0.130 |
Why?
|
Perception | 1 | 2023 | 1197 | 0.130 |
Why?
|
Pain, Postoperative | 2 | 2024 | 1740 | 0.130 |
Why?
|
Intraoperative Period | 3 | 2018 | 510 | 0.130 |
Why?
|
Neoplasm, Residual | 1 | 2021 | 1008 | 0.130 |
Why?
|
Digestive System Surgical Procedures | 1 | 2021 | 572 | 0.130 |
Why?
|
Benchmarking | 2 | 2020 | 1045 | 0.130 |
Why?
|
Neoplasm Invasiveness | 4 | 2021 | 3597 | 0.130 |
Why?
|
Risk Factors | 7 | 2023 | 74213 | 0.130 |
Why?
|
Jejunal Neoplasms | 1 | 2015 | 19 | 0.130 |
Why?
|
Disease-Free Survival | 6 | 2024 | 6815 | 0.130 |
Why?
|
Ileal Neoplasms | 1 | 2015 | 20 | 0.130 |
Why?
|
Cysts | 1 | 2021 | 681 | 0.130 |
Why?
|
Specialties, Surgical | 2 | 2010 | 389 | 0.130 |
Why?
|
Laparotomy | 1 | 2018 | 457 | 0.130 |
Why?
|
Peritoneal Neoplasms | 1 | 2022 | 711 | 0.120 |
Why?
|
Age Factors | 2 | 2023 | 18398 | 0.120 |
Why?
|
Travel | 1 | 2021 | 796 | 0.120 |
Why?
|
Photons | 1 | 2019 | 589 | 0.120 |
Why?
|
Common Bile Duct Diseases | 1 | 2014 | 36 | 0.120 |
Why?
|
Chi-Square Distribution | 1 | 2021 | 3416 | 0.120 |
Why?
|
Palliative Care | 2 | 2020 | 3598 | 0.120 |
Why?
|
New York City | 1 | 2017 | 731 | 0.120 |
Why?
|
Phagocytosis | 2 | 2010 | 1528 | 0.120 |
Why?
|
Lymph Node Excision | 2 | 2024 | 1271 | 0.120 |
Why?
|
Common Bile Duct | 1 | 2014 | 106 | 0.120 |
Why?
|
Natural Language Processing | 1 | 2023 | 1163 | 0.110 |
Why?
|
Young Adult | 9 | 2021 | 59255 | 0.110 |
Why?
|
Camptothecin | 1 | 2017 | 591 | 0.110 |
Why?
|
Cholecystectomy | 1 | 2016 | 406 | 0.110 |
Why?
|
Registries | 4 | 2023 | 8224 | 0.110 |
Why?
|
Neutrophils | 2 | 2020 | 3767 | 0.110 |
Why?
|
Triage | 1 | 2020 | 986 | 0.110 |
Why?
|
Proportional Hazards Models | 4 | 2020 | 12463 | 0.110 |
Why?
|
Prospective Studies | 12 | 2024 | 54426 | 0.110 |
Why?
|
Cytokines | 4 | 2012 | 7396 | 0.110 |
Why?
|
Radiotherapy | 1 | 2019 | 1499 | 0.100 |
Why?
|
Clinical Competence | 3 | 2020 | 4793 | 0.100 |
Why?
|
Interviews as Topic | 1 | 2020 | 2696 | 0.100 |
Why?
|
Disease Progression | 5 | 2022 | 13510 | 0.100 |
Why?
|
Endoscopy, Digestive System | 1 | 2015 | 351 | 0.100 |
Why?
|
Pancreatitis, Acute Necrotizing | 1 | 2014 | 173 | 0.100 |
Why?
|
Cholangitis, Sclerosing | 1 | 2014 | 177 | 0.100 |
Why?
|
Neoplasms | 4 | 2022 | 22173 | 0.100 |
Why?
|
Cell Transformation, Neoplastic | 2 | 2020 | 2827 | 0.100 |
Why?
|
Liver Diseases | 1 | 2021 | 1298 | 0.100 |
Why?
|
Heparin | 1 | 2019 | 1634 | 0.100 |
Why?
|
Lymphocytes | 1 | 2020 | 2612 | 0.100 |
Why?
|
Cooperative Behavior | 1 | 2019 | 1505 | 0.100 |
Why?
|
Quality of Life | 3 | 2023 | 13367 | 0.100 |
Why?
|
Neoplasm Metastasis | 2 | 2020 | 4915 | 0.100 |
Why?
|
Gallbladder | 1 | 2013 | 308 | 0.100 |
Why?
|
Fluorodeoxyglucose F18 | 4 | 2022 | 2010 | 0.100 |
Why?
|
Terminal Care | 1 | 2023 | 1761 | 0.100 |
Why?
|
Fellowships and Scholarships | 1 | 2020 | 1117 | 0.100 |
Why?
|
Debridement | 1 | 2014 | 493 | 0.100 |
Why?
|
Down-Regulation | 1 | 2018 | 2919 | 0.090 |
Why?
|
Cholestasis | 1 | 2014 | 378 | 0.090 |
Why?
|
Dexamethasone | 1 | 2018 | 1948 | 0.090 |
Why?
|
Rewarming | 1 | 2010 | 64 | 0.090 |
Why?
|
Cesarean Section | 1 | 2019 | 1398 | 0.090 |
Why?
|
Postoperative Period | 3 | 2020 | 1814 | 0.090 |
Why?
|
Incidental Findings | 1 | 2015 | 697 | 0.090 |
Why?
|
Liver | 2 | 2024 | 7529 | 0.090 |
Why?
|
Splenectomy | 1 | 2011 | 391 | 0.090 |
Why?
|
Urination Disorders | 1 | 2011 | 238 | 0.090 |
Why?
|
Risk Assessment | 4 | 2020 | 23996 | 0.080 |
Why?
|
Hospitalization | 2 | 2019 | 10721 | 0.080 |
Why?
|
Communication | 1 | 2023 | 3873 | 0.080 |
Why?
|
Steroids | 1 | 2014 | 929 | 0.080 |
Why?
|
Glucocorticoids | 1 | 2018 | 2161 | 0.080 |
Why?
|
Cholecystectomy, Laparoscopic | 1 | 2011 | 232 | 0.080 |
Why?
|
Cold Temperature | 1 | 2012 | 785 | 0.080 |
Why?
|
Medicare | 3 | 2023 | 6770 | 0.080 |
Why?
|
Molecular Targeted Therapy | 1 | 2020 | 2811 | 0.080 |
Why?
|
Students, Medical | 1 | 2021 | 1936 | 0.080 |
Why?
|
Radiopharmaceuticals | 3 | 2024 | 2651 | 0.080 |
Why?
|
Lipopolysaccharides | 3 | 2011 | 2206 | 0.070 |
Why?
|
Opioid-Related Disorders | 1 | 2023 | 2164 | 0.070 |
Why?
|
Gastroesophageal Reflux | 1 | 2015 | 819 | 0.070 |
Why?
|
Standard of Care | 2 | 2022 | 551 | 0.070 |
Why?
|
Reproducibility of Results | 2 | 2020 | 20099 | 0.070 |
Why?
|
Publication Bias | 1 | 2008 | 160 | 0.070 |
Why?
|
Emigration and Immigration | 1 | 2010 | 397 | 0.070 |
Why?
|
Anti-Infective Agents, Local | 1 | 2010 | 247 | 0.070 |
Why?
|
History, 21st Century | 1 | 2013 | 1567 | 0.070 |
Why?
|
Practice Guidelines as Topic | 3 | 2021 | 7391 | 0.070 |
Why?
|
Prostatic Hyperplasia | 1 | 2011 | 521 | 0.070 |
Why?
|
Colectomy | 1 | 2012 | 688 | 0.070 |
Why?
|
Liver Transplantation | 1 | 2018 | 2330 | 0.070 |
Why?
|
Cohort Studies | 6 | 2020 | 41493 | 0.070 |
Why?
|
Urban Health | 1 | 2009 | 532 | 0.070 |
Why?
|
Biopsy, Needle | 1 | 2011 | 1626 | 0.070 |
Why?
|
Biopsy | 2 | 2015 | 6766 | 0.070 |
Why?
|
California | 2 | 2021 | 1430 | 0.070 |
Why?
|
Evaluation Studies as Topic | 1 | 2008 | 1624 | 0.070 |
Why?
|
Rare Diseases | 1 | 2011 | 622 | 0.070 |
Why?
|
Temperature | 2 | 2010 | 2226 | 0.070 |
Why?
|
Socioeconomic Factors | 1 | 2020 | 7827 | 0.060 |
Why?
|
Intensive Care Units | 1 | 2019 | 3744 | 0.060 |
Why?
|
Colon | 2 | 2011 | 1792 | 0.060 |
Why?
|
Virulence | 1 | 2009 | 1303 | 0.060 |
Why?
|
Incidence | 3 | 2019 | 21355 | 0.060 |
Why?
|
Abdomen | 1 | 2011 | 1128 | 0.060 |
Why?
|
Fibrosis | 2 | 2024 | 2049 | 0.060 |
Why?
|
Cytoskeleton | 1 | 2010 | 1170 | 0.060 |
Why?
|
Thioacetamide | 1 | 2024 | 22 | 0.060 |
Why?
|
Diethylnitrosamine | 1 | 2024 | 45 | 0.060 |
Why?
|
CD4 Lymphocyte Count | 1 | 2011 | 2571 | 0.060 |
Why?
|
Carbon Tetrachloride | 1 | 2024 | 72 | 0.060 |
Why?
|
Antigen Presentation | 1 | 2010 | 1251 | 0.060 |
Why?
|
Fatigue | 1 | 2011 | 1552 | 0.060 |
Why?
|
Appendectomy | 1 | 2008 | 433 | 0.060 |
Why?
|
Europe | 2 | 2021 | 3422 | 0.060 |
Why?
|
Leukocytes | 1 | 2012 | 2026 | 0.060 |
Why?
|
Multiple Trauma | 1 | 2007 | 369 | 0.060 |
Why?
|
Monocytes | 2 | 2010 | 2570 | 0.060 |
Why?
|
Immunity, Cellular | 1 | 2010 | 1560 | 0.060 |
Why?
|
Decision Making | 1 | 2018 | 3929 | 0.060 |
Why?
|
Gallium Radioisotopes | 1 | 2024 | 195 | 0.060 |
Why?
|
Health Services Accessibility | 1 | 2021 | 5440 | 0.060 |
Why?
|
Curriculum | 1 | 2017 | 3743 | 0.060 |
Why?
|
Pneumothorax | 1 | 2007 | 386 | 0.050 |
Why?
|
Meta-Analysis as Topic | 1 | 2008 | 1380 | 0.050 |
Why?
|
Morphine Derivatives | 1 | 2023 | 42 | 0.050 |
Why?
|
Flow Cytometry | 2 | 2010 | 5869 | 0.050 |
Why?
|
Hypoglycemia | 1 | 2010 | 883 | 0.050 |
Why?
|
Leukocyte Count | 2 | 2020 | 1596 | 0.050 |
Why?
|
Actins | 1 | 2010 | 2050 | 0.050 |
Why?
|
Immunoglobulin G | 1 | 2014 | 4544 | 0.050 |
Why?
|
Cell Line, Tumor | 3 | 2024 | 16986 | 0.050 |
Why?
|
Reoperation | 3 | 2021 | 4303 | 0.050 |
Why?
|
Drug Resistance, Bacterial | 1 | 2009 | 1048 | 0.050 |
Why?
|
Anti-Infective Agents | 1 | 2009 | 983 | 0.050 |
Why?
|
Adult Children | 1 | 2022 | 103 | 0.050 |
Why?
|
Anemia | 1 | 2011 | 1509 | 0.050 |
Why?
|
Drug Substitution | 1 | 2024 | 290 | 0.050 |
Why?
|
Coronary Artery Bypass | 1 | 2011 | 2188 | 0.050 |
Why?
|
Immune Tolerance | 1 | 2011 | 2302 | 0.050 |
Why?
|
Fibrinolysis | 1 | 2003 | 332 | 0.050 |
Why?
|
Sensitivity and Specificity | 3 | 2022 | 14666 | 0.050 |
Why?
|
Postoperative Care | 2 | 2023 | 1468 | 0.050 |
Why?
|
Gene Expression Regulation, Neoplastic | 2 | 2024 | 8552 | 0.050 |
Why?
|
Analysis of Variance | 1 | 2010 | 6228 | 0.050 |
Why?
|
Melanoma | 1 | 2020 | 5709 | 0.050 |
Why?
|
Quality of Health Care | 2 | 2021 | 4330 | 0.050 |
Why?
|
Glucose | 2 | 2010 | 4346 | 0.050 |
Why?
|
Diabetes Mellitus | 1 | 2019 | 5841 | 0.050 |
Why?
|
Primary Prevention | 1 | 2008 | 1186 | 0.050 |
Why?
|
Frozen Sections | 1 | 2021 | 153 | 0.050 |
Why?
|
Predictive Value of Tests | 4 | 2020 | 15266 | 0.040 |
Why?
|
Health Facility Size | 2 | 2010 | 61 | 0.040 |
Why?
|
Analgesia, Epidural | 1 | 2024 | 332 | 0.040 |
Why?
|
Wounds, Nonpenetrating | 1 | 2007 | 807 | 0.040 |
Why?
|
Skin Neoplasms | 1 | 2020 | 5821 | 0.040 |
Why?
|
Critical Illness | 2 | 2010 | 2723 | 0.040 |
Why?
|
Calcium Channel Blockers | 1 | 2023 | 694 | 0.040 |
Why?
|
Genes, MHC Class I | 1 | 2021 | 235 | 0.040 |
Why?
|
Arthroplasty, Replacement, Hip | 1 | 2011 | 1413 | 0.040 |
Why?
|
Hematologic Tests | 1 | 2021 | 239 | 0.040 |
Why?
|
Arthroplasty, Replacement, Knee | 1 | 2011 | 1393 | 0.040 |
Why?
|
Gene Expression Profiling | 3 | 2024 | 9420 | 0.040 |
Why?
|
Deoxycytidine | 1 | 2024 | 877 | 0.040 |
Why?
|
Cross Infection | 1 | 2009 | 1422 | 0.040 |
Why?
|
Bile Ducts, Intrahepatic | 1 | 2021 | 296 | 0.040 |
Why?
|
Preoperative Period | 1 | 2022 | 551 | 0.040 |
Why?
|
Efficiency | 1 | 2022 | 476 | 0.040 |
Why?
|
ABO Blood-Group System | 1 | 2021 | 380 | 0.040 |
Why?
|
Therapies, Investigational | 1 | 2020 | 111 | 0.040 |
Why?
|
Heterocyclic Compounds | 1 | 2020 | 246 | 0.040 |
Why?
|
New York | 1 | 2021 | 874 | 0.040 |
Why?
|
Vasodilation | 1 | 2003 | 962 | 0.040 |
Why?
|
Vasculitis | 1 | 2003 | 521 | 0.040 |
Why?
|
Poisson Distribution | 1 | 2020 | 504 | 0.040 |
Why?
|
Risk | 1 | 2011 | 9610 | 0.040 |
Why?
|
Molecular Probes | 1 | 2020 | 309 | 0.040 |
Why?
|
Germany | 1 | 2020 | 875 | 0.040 |
Why?
|
Mice, Nude | 1 | 2024 | 3614 | 0.040 |
Why?
|
Immunohistochemistry | 1 | 2011 | 11076 | 0.040 |
Why?
|
Drug Screening Assays, Antitumor | 1 | 2020 | 718 | 0.040 |
Why?
|
Postoperative Hemorrhage | 1 | 2021 | 415 | 0.040 |
Why?
|
Platelet Count | 1 | 2020 | 781 | 0.040 |
Why?
|
Interleukin-6 | 2 | 2024 | 3208 | 0.040 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2011 | 4580 | 0.040 |
Why?
|
Nanomedicine | 1 | 2020 | 290 | 0.040 |
Why?
|
Cell Communication | 1 | 2024 | 1657 | 0.040 |
Why?
|
Tissue Plasminogen Activator | 1 | 2003 | 1164 | 0.040 |
Why?
|
Abdominal Abscess | 1 | 2018 | 153 | 0.040 |
Why?
|
Sequence Analysis, RNA | 1 | 2024 | 2020 | 0.030 |
Why?
|
Organometallic Compounds | 1 | 2020 | 647 | 0.030 |
Why?
|
Aftercare | 1 | 2023 | 914 | 0.030 |
Why?
|
Tumor Necrosis Factor-alpha | 2 | 2010 | 4352 | 0.030 |
Why?
|
Animals | 6 | 2024 | 168467 | 0.030 |
Why?
|
MicroRNAs | 1 | 2012 | 3816 | 0.030 |
Why?
|
Organoplatinum Compounds | 1 | 2017 | 407 | 0.030 |
Why?
|
Nursing Homes | 1 | 2023 | 1082 | 0.030 |
Why?
|
Inflammatory Bowel Diseases | 1 | 2010 | 2422 | 0.030 |
Why?
|
Operating Rooms | 1 | 2021 | 789 | 0.030 |
Why?
|
Frail Elderly | 1 | 2020 | 765 | 0.030 |
Why?
|
Immunity | 1 | 2021 | 996 | 0.030 |
Why?
|
Laparoscopes | 1 | 2014 | 37 | 0.030 |
Why?
|
Fibroblasts | 1 | 2024 | 4141 | 0.030 |
Why?
|
Mice | 4 | 2024 | 81533 | 0.030 |
Why?
|
Treatment Failure | 1 | 2019 | 2644 | 0.030 |
Why?
|
Molecular Imaging | 1 | 2020 | 815 | 0.030 |
Why?
|
Activities of Daily Living | 1 | 2022 | 2421 | 0.030 |
Why?
|
China | 1 | 2019 | 2374 | 0.030 |
Why?
|
Biomedical Research | 1 | 2008 | 3429 | 0.030 |
Why?
|
Radiation Injuries | 1 | 2019 | 1189 | 0.030 |
Why?
|
Urinary Tract Infections | 1 | 2018 | 802 | 0.020 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2009 | 10212 | 0.020 |
Why?
|
Collagen | 1 | 2020 | 2638 | 0.020 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2020 | 3603 | 0.020 |
Why?
|
Faculty, Medical | 1 | 2020 | 1204 | 0.020 |
Why?
|
ROC Curve | 1 | 2019 | 3579 | 0.020 |
Why?
|
Brachytherapy | 1 | 2019 | 1223 | 0.020 |
Why?
|
Cholangiopancreatography, Endoscopic Retrograde | 1 | 2014 | 506 | 0.020 |
Why?
|
Blood Circulation | 1 | 2012 | 248 | 0.020 |
Why?
|
Acute Disease | 1 | 2022 | 7237 | 0.020 |
Why?
|
Buffers | 1 | 2011 | 146 | 0.020 |
Why?
|
Job Application | 1 | 2010 | 38 | 0.020 |
Why?
|
Mice, Inbred C57BL | 2 | 2024 | 22172 | 0.020 |
Why?
|
Constriction, Pathologic | 1 | 2014 | 1096 | 0.020 |
Why?
|
Peritoneal Cavity | 1 | 2011 | 135 | 0.020 |
Why?
|
Endothelium, Vascular | 1 | 2003 | 4431 | 0.020 |
Why?
|
Severity of Illness Index | 1 | 2008 | 15843 | 0.020 |
Why?
|
Profilins | 1 | 2010 | 65 | 0.020 |
Why?
|
Bacterial Load | 1 | 2011 | 152 | 0.020 |
Why?
|
Survivors | 1 | 2021 | 2371 | 0.020 |
Why?
|
Mannitol | 1 | 2010 | 180 | 0.020 |
Why?
|
Forecasting | 1 | 2019 | 2928 | 0.020 |
Why?
|
Qualitative Research | 1 | 2021 | 3023 | 0.020 |
Why?
|
Macrophages, Peritoneal | 1 | 2011 | 238 | 0.020 |
Why?
|
Licensure, Medical | 1 | 2010 | 71 | 0.020 |
Why?
|
Osmolar Concentration | 1 | 2010 | 659 | 0.020 |
Why?
|
Stomach | 1 | 2014 | 696 | 0.020 |
Why?
|
Patient Discharge | 1 | 2023 | 3443 | 0.020 |
Why?
|
Recovery of Function | 1 | 2020 | 2979 | 0.020 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 2019 | 3769 | 0.020 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2024 | 5305 | 0.020 |
Why?
|
Drug Delivery Systems | 1 | 2020 | 2226 | 0.020 |
Why?
|
Insurance, Health | 1 | 2021 | 2498 | 0.020 |
Why?
|
Rats | 1 | 2024 | 23741 | 0.020 |
Why?
|
Scotland | 1 | 2008 | 143 | 0.020 |
Why?
|
Risk Adjustment | 1 | 2012 | 600 | 0.020 |
Why?
|
Fibroblast Growth Factor 2 | 1 | 2010 | 592 | 0.020 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2011 | 12148 | 0.020 |
Why?
|
Toll-Like Receptors | 1 | 2011 | 589 | 0.020 |
Why?
|
Hospitals | 1 | 2021 | 3882 | 0.020 |
Why?
|
Hospitals, Teaching | 1 | 2012 | 1156 | 0.020 |
Why?
|
Diagnostic Errors | 1 | 2014 | 1265 | 0.020 |
Why?
|
Pneumonia | 1 | 2018 | 2143 | 0.020 |
Why?
|
Cell Count | 1 | 2011 | 1835 | 0.020 |
Why?
|
Smoking | 1 | 2023 | 9053 | 0.020 |
Why?
|
Analgesics, Opioid | 1 | 2023 | 3808 | 0.020 |
Why?
|
Equipment Design | 1 | 2014 | 3511 | 0.020 |
Why?
|
Child | 1 | 2013 | 80156 | 0.020 |
Why?
|
Disease Models, Animal | 1 | 2024 | 18253 | 0.020 |
Why?
|
Protein Biosynthesis | 1 | 2012 | 2112 | 0.020 |
Why?
|
Cytoskeletal Proteins | 1 | 2010 | 1342 | 0.010 |
Why?
|
Immunotherapy | 1 | 2020 | 4652 | 0.010 |
Why?
|
Emergency Treatment | 1 | 2008 | 496 | 0.010 |
Why?
|
Ligands | 1 | 2011 | 3272 | 0.010 |
Why?
|
Precancerous Conditions | 1 | 2010 | 980 | 0.010 |
Why?
|
Injections, Intra-Arterial | 1 | 2003 | 182 | 0.010 |
Why?
|
Exercise | 1 | 2020 | 5890 | 0.010 |
Why?
|
Plethysmography | 1 | 2003 | 175 | 0.010 |
Why?
|
Nitroprusside | 1 | 2003 | 272 | 0.010 |
Why?
|
Bradykinin | 1 | 2003 | 208 | 0.010 |
Why?
|
Fever | 1 | 2010 | 1618 | 0.010 |
Why?
|
Algorithms | 1 | 2023 | 14032 | 0.010 |
Why?
|
Electronic Health Records | 1 | 2019 | 4811 | 0.010 |
Why?
|
Nitric Oxide | 1 | 2011 | 2135 | 0.010 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2010 | 3778 | 0.010 |
Why?
|
Brachial Artery | 1 | 2003 | 366 | 0.010 |
Why?
|
Signal Transduction | 1 | 2024 | 23447 | 0.010 |
Why?
|
Acetylcholine | 1 | 2003 | 629 | 0.010 |
Why?
|
Endotoxins | 1 | 2003 | 520 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2021 | 26127 | 0.010 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2010 | 2898 | 0.010 |
Why?
|
Diagnosis, Differential | 1 | 2014 | 12975 | 0.010 |
Why?
|
Computational Biology | 1 | 2010 | 3517 | 0.010 |
Why?
|
Pregnancy | 1 | 2019 | 29876 | 0.010 |
Why?
|
Cells, Cultured | 1 | 2012 | 18965 | 0.010 |
Why?
|
Respiration, Artificial | 1 | 2007 | 2630 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 2012 | 11904 | 0.010 |
Why?
|
Membrane Proteins | 1 | 2010 | 7858 | 0.010 |
Why?
|
Double-Blind Method | 1 | 2003 | 12341 | 0.000 |
Why?
|